Amadix
Amadix is a biotechnology company focused on the development and commercialization of innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company aims to enhance early cancer detection through non-invasive methods, significantly improving patient outcomes and reducing the complications associated with traditional invasive procedures like tumor biopsies. Amadix's flagship product, Colofast, is a non-invasive blood test designed for the screening of colorectal cancer and advanced adenoma diagnosis, targeting the high mortality rate associated with this disease. The company is committed to validating its products through international multicenter studies to ensure clinical efficacy before global commercialization. The team at Amadix comprises experienced professionals with extensive backgrounds in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by an independent board of advisors with deep expertise in oncology and diagnostics, guiding the company's strategic and commercial efforts.
1 past transactions
Transbiomed
Acquisition in 2013
Transbiomed is a biotechnology company based in Barcelona, Spain, specializing in non-invasive molecular diagnostic therapies. The company has developed a urine test designed for the early diagnosis of prostate cancer, positioning it as an alternative to traditional biopsy methods. Transbiomed is currently focused on the clinical validation of its innovative diagnostic approach across various hospitals in Spain. The company's strategy encompasses the discovery and development of biomarkers, advancing through industrial prototyping, product design, and pivotal clinical trials. Following these stages, Transbiomed aims to license its products to major pharmaceutical firms for commercialization. The company plans to initiate the commercialization of its prostate cancer diagnostic device by 2013.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.